Summit Therapeutics presented data on a cancer drug targeting the immune system at the ASCO conference in Chicago.
1 report, 1 independent
Updated Jun 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Summit Therapeutics presented data on a cancer drug targeting the immune system at the ASCO conference in Chicago.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Chinese biopharma is gaining ground, producing oncology drugs that rival established Western pharmaceuticals like those associated with Merck.Also in this story
- LG Chem and OTR Therapeutics announce a strategic collaboration to leverage China's life science ecosystem for oncology R&D.
- Institutional investors bought and sold stock in Summit Therapeutics.
The entities involved
-
Merck
public company in Indonesia
-
Cancer
government organization in Paris, France
Nothing else this week.
Related events
- Moderna and Merck are developing a combination therapy using Keytruda.
- Merck's stock price increased following positive drug performance involving Summit Therapeutics.
- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
- A market rally was observed in the biotech sector, driven by positive cancer vaccine news, causing Eli Lilly shares to rise.
- A clinical trial comparing volrustomig against Keytruda was reported, alongside news that Union Investment is an AstraZeneca shareholder.